Twist Bioscience Co. (NASDAQ:TWST) COO Sells $140,400.75 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,845 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $140,400.75. Following the completion of the sale, the chief operating officer now directly owns 269,199 shares in the company, valued at $13,284,970.65. This trade represents a 1.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The shares were sold at an average price of $50.17, for a total value of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $52.30 on Friday. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The firm’s 50 day moving average price is $48.84 and its 200-day moving average price is $46.32. The company has a quick ratio of 4.54, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.75) earnings per share. As a group, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience during the third quarter worth about $43,992,000. State Street Corp boosted its stake in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Wellington Management Group LLP grew its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the last quarter. Jennison Associates LLC increased its stake in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after purchasing an additional 302,884 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after buying an additional 237,772 shares during the last quarter.

Analyst Upgrades and Downgrades

TWST has been the topic of several research reports. Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Scotiabank boosted their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.